Cognitive Impairment in Elderly People with Type 2 Diabetes: Is There an Association and Why?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The authors would like to acknowledge the contribution of the co-investigators, collaborators and staff of the Edinburgh Type 2 Diabetes Study (ET2DS). The main funding for the ET2DS was provided by the Medical Research Council. The authors are extremely grateful to all the participants of the ET2DS. MWJ Strachan declares associations with Eli Lilly, GlaxoSmithKline, Pfizer, Sanofi-Aventis, Takeda and Novo Nordisk. JF Price declares associations with Bayer Healthcare and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors would like to acknowledge the contribution of the co-investigators, collaborators and staff of the Edinburgh Type 2 Diabetes Study (ET2DS). The main funding for the ET2DS was provided by the Medical Research Council. The authors are extremely grateful to all the participants of the ET2DS. MWJ Strachan declares associations with Eli Lilly, GlaxoSmithKline, Pfizer, Sanofi-Aventis, Takeda and Novo Nordisk. JF Price declares associations with Bayer Healthcare and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.